ESA Meta-Analysis Underscores Survival Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Next step for FDA and Amgen on Aranesp: Finalizing REMS and agreeing on new trials.
You may also be interested in...
ESA REMS Allows Oncologists A Year To Enroll In Patient Education Program
The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment, but stops short of some more restrictive REMS options such as patient registries or controlled distribution
ESA REMS Allows Oncologists A Year To Enroll In Patient Education Program
The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment, but stops short of some more restrictive REMS options such as patient registries or controlled distribution
ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits
The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.